IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2146
Positioning
Market Dominance
Manufacturing
Medical Equipment
$5.5B
Quentin S. Blackford
iRhythm Technologies, Inc. provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company's Zio XT and AT monitors, single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$IRTC iRhythm Technologies, Inc. | 49 | 51 | 54 | 51 | - | - | -63.0% | -9.4% | 70.0% | -17.3% | -15.2% | 30.3% | 0.0% | 568.0x | $5.5B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
iRhythm Technologies, Inc. (IRTC) receives a "Reduce" rating with a composite score of 49.1/100. It ranks #2146 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Quentin S. Blackford
Chief Executive Officer
Labor Force
1,790
51
42
76
Audit Verdict: Average governance indicators based on financial metrics.
No recent insider transactions available for IRTC
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for IRTC.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROIC -11.5% vs WACC 8.6% (spread -20.2%)
GM 70% vs sector 43%, OM -17% vs sector 1%
Capital turnover 1.90x
Rev growth 30%, 10yr history
Interest coverage -17.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
iRhythm Technologies, Inc. receives a Reduce rating from our analysis, with a composite score of 49.1/100 and 2 out of 5 stars, ranking #2146 out of 7,333 stocks. IRTC's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 51/100, IRTC shows adequate but unremarkable business quality. The company reports a return on equity of -63.0% (sector avg: -2.5%), gross margins of 70.0% (sector avg: 42.5%), net margins of -15.2% (sector avg: -0.2%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
IRTC's value score of 54/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/B ratio of 31.84x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
With an investment score of 42/100, IRTC exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 30.3% vs. a sector average of 5.9% and a return on assets of -9.4% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
IRTC demonstrates moderate momentum with a score of 51/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at 30.3% year-over-year, while a beta of 0.82 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
IRTC shows good financial stability with a score of 76/100. Key stability metrics include a beta of 0.82 and a debt-to-equity ratio of 568.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
iRhythm Technologies, Inc.'s short interest score of 38/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 568.00x). At $5.5B (mid-cap), IRTC carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
iRhythm Technologies, Inc. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2146 of 7,333 overall (71st percentile). Key comparisons include ROE of -63.0% trailing the -2.5% sector median and operating margins of -17.3% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While IRTC currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (38) would have the largest impact on the composite score.
ROE 2442% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 65% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 1437% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate iRhythm Technologies, Inc. (IRTC) as a Reduce with a composite score of 49.1/100 at a current price of $137.06. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in stability (76th percentile) and value (54th percentile), which together account for the majority of the composite score. All factors score above the 40th percentile, indicating no material weakness in the quantitative profile. We assign a No Moat rating (32/100), High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
iRhythm Technologies, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 49.1/100 places it at rank #2146 in our full 7,333-stock universe. At $5.5B in market capitalization, iRhythm Technologies, Inc. is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 30%, though momentum at the 51th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 70% (+27.5pp vs sector) narrow to operating margins of -17% (-18.5pp vs sector) and net margins of -15.2%, yielding a gross-to-net conversion rate of -22%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $137.06, iRhythm Technologies, Inc. is trading near fair value based on current fundamentals. Our value factor score of 54/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 31.8x, P/S of 7.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 70% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 30% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
The Reduce rating (composite 49.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (568% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Thin net margins of -15.2% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to iRhythm Technologies, Inc.. Key risk factors include significant leverage (568% debt-to-equity), current negative profitability (net margin -15.2%), the combination of leverage (568% D/E) and thin margins (-15.2% net) amplifies downside risk. The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: significant leverage (568% debt-to-equity); current negative profitability (net margin -15.2%); the combination of leverage (568% D/E) and thin margins (-15.2% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 76th percentile and quality factor at the 51th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 70% provide a buffer against cost pressures; above-average stability (76th percentile) suggests predictable business dynamics. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate iRhythm Technologies, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-63.0%), elevated leverage (568% D/E), negative profitability, weak asset returns (ROA -9.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — iRhythm Technologies, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, iRhythm Technologies, Inc. receives a Reduce rating with a composite score of 49.1/100 (rank #2146 of 7,333). Our quantitative framework assigns a No Moat (32/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 55/100.
Our analysis does not support a constructive view on iRhythm Technologies, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign iRhythm Technologies, Inc. a meaningful economic moat, scoring 32/100 on our composite assessment. The ROIC-WACC spread of -20.2% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 13/20.
The strongest moat sources are growth durability (13/20) and margin superiority (12.9/20). Rev growth 30%, 10yr history. GM 70% vs sector 43%, OM -17% vs sector 1%. These pillars form the core of iRhythm Technologies, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include financial resilience (0.8/20) and economic value creation (2.2/20). Interest coverage -17.5x. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect iRhythm Technologies, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 70% providing a solid profitability foundation, robust top-line growth of 30% expanding the revenue base. The margin cascade from 70% gross to -17% operating to -15.2% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 51th percentile.
The margin profile shows gross margins of 70%, operating margins of -17%, net margins of -15.2%. Return metrics include ROE of -63.0% and ROA of -9.4%. Relative to the Manufacturing sector, gross margins are 27.5 percentage points above the sector median of 43%, and ROE of -63.0% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 568%, which may limit financial flexibility, revenue growth of 30%. The sector median D/E is 0%, putting iRhythm Technologies, Inc. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Above 50MA
37.18%
Net New Highs
+51081

Robert W. Baird has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) from $220.00 to $200.00, while maintaining an "outperform" rating, suggesting a potential upside of 36.14%. Despite the price target cut, and a 7.5% share drop, iRhythm exceeded quarterly earnings expectations with an EPS of $0.29 (vs. $0.02 expected) and revenue of $208.9M, a 27.1% year-over-year increase. The company remains unprofitable with a negative net margin and P/E ratio, and recent insider sales have occurred.

iRhythm Tech (NASDAQ: IRTC) exceeded analyst expectations for its fiscal fourth quarter, reporting an EPS of $0.17 against an estimated $0.01, and revenue of $208.9M, surpassing the consensus of $201.08M. The company also provided strong Q1 2026 revenue guidance, projecting between $870.00M and $880.00M, above analyst estimates. Despite recent stock fluctuations, iRhythm Tech maintains a "good performance" financial health rating according to InvestingPro.
iRhythm Holdings, Inc. announced its financial results for the fourth quarter and full year 2025, reporting significant revenue growth and profitability milestones. The company achieved a record revenue of $208.9 million in Q4 2025, a 27.1% increase, and registered its first quarter of positive GAAP net income. For the full year, revenue reached $747.1 million, a 26.2% increase, and the company expects continued growth in 2026 with projected revenues of $870 million to $880 million.

iRhythm Technologies (NASDAQ:IRTC) reported its quarterly earnings, announcing an EPS of $0.29, significantly beating analysts' estimates of $0.02. Despite the positive EPS surprise, the company remains unprofitable with negative ROE and net margin. Following the announcement, IRTC shares rose by $5.03 to $158.88 on above-average volume, and several analysts increased their price targets, contributing to a "Moderate Buy" consensus rating.

This article evaluates three healthcare stocks, recommending two for potential market-beating returns and advising against one. Organon (OGN) is suggested to be avoided due to declining revenue, less profitable sales, and increased capital intensity. iRhythm Technologies (IRTC) and Alignment Healthcare (ALHC) are highlighted as promising due to strong revenue growth, improved operating margins, and positive free cash flow, respectively.